Highlights Novelion Therapeutics Inc. Toronto S.E.

Equities

NVLN

CA67001K2020

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-2.92%	-.--%

2022	Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022	CI
2020	Novelion Therapeutics Inc. Announces Management Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022	22-03-28	CI
Novelion Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI
Novelion Therapeutics Inc. Provides the Earnings Guidance for the Year 2019	19-05-07	CI
Novelion Therapeutics Inc. Provides Revenue Guidance for the Year 2019	19-03-14	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018	19-03-14	CI
Novelion Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Net Product Sales Guidance for 2018 and 2019	18-11-09	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Financial Results for the Quarter and Six Months Ended June 30, 2018; Provides Revenue Guidance for the Year 2019	18-08-07	CI
Novelion Therapeutics Announces Marketing Authorization for Myalepta in the European Union to Treat Generalized and Partial Lipodystrophy	18-07-31	CI
Novelion Therapeutics Inc. Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions	18-06-25	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-10	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-14	CI
Novelion Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Reiterates Revenue Guidance for the Full Year 2017	17-11-09	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Financial Results for the Quarter and Six Months Ended June 30, 2017; Revises Revenue Guidance for the Full Year of 2017	17-08-08	CI
Novelion Therapeutics Inc. Announces Presentation of Metreleptin Data at American Diabetes Association	17-06-12	CI
Novelion Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Reiterates Revenue Guidance for the Year 2017	17-05-09	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Sales Guidance for the Full Year 2017	17-03-15	CI
Novelion Therapeutics Inc. Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency	17-01-23	CI
Novelion Therapeutics Inc. Revises Net Product Sales Guidance for the Year 2016; Provides Net Product Sales Guidance for the Year 2017	17-01-09	CI
Novelion Therapeutics’ Subsidiary Files for European Approval for Metreleptin as a Treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy	16-12-22	CI
QLT Inc. completed the acquisition of Aegerion Pharmaceuticals, Inc..	16-11-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Novelion Therapeutics Inc. Toronto S.E.

Equities

NVLN

CA67001K2020

Highlights

Filters